Biofrontera AG (B8F) - Financial and Strategic SWOT Analysis Review

  • ID: 4284867
  • SWOT Analysis
  • 25 pages
  • GlobalData
  • Biofrontera AG
1 of 5

FEATURED COMPANIES

  • Almirall Hermal GmbH
  • Galderma SA
  • Intendis GmbH
  • MIKA Pharma GmbH
  • MORE
Summary

Biofrontera AG (Biofrontera) is a biopharmaceutical company that develops dermatological medicine and products. The company’s products comprise ameluz, BF-RhodoLED and belixos. Its prescription drug ameluz is used for the treatment of skin disease actinic keratosis. Biofrontera’s BF-RhodoLED is a lamp used for photodynamic therapy with LEDs emitting red light. The company’s cosmeceutical line of products, belixos is used for regenerative care of reddened and inflamed skin. Its belixos line of products include belixos creme, belixos liquid, belixos gel, belixos to go and belixos protect. The company’s pipeline products include BF-1 and BF-derm1. It operates in the US and Germany. Biofrontera is headquartered in Leverkusen, Germany.

Biofrontera AG Key Recent Developments

Jan 23, 2018: Biofrontera receives 12-month follow-up results of the Phase III trial for daylight PDT
Nov 27, 2017: Biofrontera Reports Financial Results for Third Quarter and First Nine Months of 2017
Nov 14, 2017: Biofrontera adjusts revenues and earnings forecast for the financial year 2017
Oct 16, 2017: Biofrontera to Present at the McGuire Woods 9th Annual Pharmaceutical and Medical Device Conference
Aug 31, 2017: Biofrontera Grows Revenues and Improves Financial Position in First Half 2017

This comprehensive SWOT profile of Biofrontera AG provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of the author’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, the author’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Biofrontera AG including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
*Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Almirall Hermal GmbH
  • Galderma SA
  • Intendis GmbH
  • MIKA Pharma GmbH
  • MORE
Section 1 - About the Company
  • Biofrontera AG - Key Information
  • Biofrontera AG - Overview
  • Biofrontera AG - Key Employees
  • Biofrontera AG - Key Employee Biographies
  • Biofrontera AG - Key Operational Heads
  • Biofrontera AG - Major Products and Services
  • Biofrontera AG - History
  • Biofrontera AG - Company Statement
  • Biofrontera AG - Locations And Subsidiaries
  • Biofrontera AG - Key Manufacturing facilities
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Biofrontera AG - Business Description
  • Biofrontera AG - Corporate Strategy
  • Biofrontera AG - SWOT Analysis
  • SWOT Analysis - Overview
  • Biofrontera AG - Strengths
  • Biofrontera AG - Weaknesses
  • Biofrontera AG - Opportunities
  • Biofrontera AG - Threats
  • Biofrontera AG - Key Competitors
Section 3 - Company Financial Performance Charts
  • Biofrontera AG - Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Appendix
  • Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
*Note: Some sections may be missing if data is unavailable for the company

List of Tables
  • Biofrontera AG, Key Information
  • Biofrontera AG, Key Ratios
  • Biofrontera AG, Share Data
  • Biofrontera AG, Major Products and Services
  • Biofrontera AG, History
  • Biofrontera AG, Key Employees
  • Biofrontera AG, Key Employee Biographies
  • Biofrontera AG, Key Operational Heads
  • Biofrontera AG, Other Locations
  • Biofrontera AG, Subsidiaries
  • Biofrontera AG, Key Manufacturing facilities
  • Biofrontera AG, Key Competitors
  • Biofrontera AG, SWOT Analysis
  • Biofrontera AG, Ratios based on current share price
  • Biofrontera AG, Annual Ratios
  • Biofrontera AG, Interim Ratios
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Biofrontera AG, Performance Chart
  • Biofrontera AG, Ratio Charts
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • MIKA Pharma GmbH
  • Intendis GmbH
  • Galderma SA
  • Almirall Hermal GmbH
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll